For a drug developer weighing a new market, a national strategy sets the direction. The practical questions come next: Where can a trial run and at what phase? Who can manufacture locally? Is there capital for a local partner and trained staff to run a facility?
Saudi Arabia’s National Biotechnology Strategy, launched in January 2024, sets the ambition: a $34.6 billion contribution to non-oil GDP by 2040 and 11,000 jobs by 2030. The more useful signal for industry is whether those practical questions are starting to get named answers. Agreements announced at the Riyadh Global Medical Biotechnology Summit (RGMBS) in September suggest they are.
Research and clinical translation
King Abdullah International Medical Research Center (KAIMRC), the research arm of King Saud bin Abdulaziz University for Health Sciences, announced a Center of Excellence for Genomics, Proteomics and Biobanking with Thermo Fisher Scientific. It also agreed research collaborations with Olink in proteomics, Tiziana Life Sciences in immunomodulation and neuroimmunology and Japan’s Chiyoda Corporation on plant-based peptide production for cancer treatment.
The newer agreements build on older ones. KAIMRC’s partnership with AstraZeneca, signed at the 2023 edition of the summit and presented at this year’s, set out a joint lab in Riyadh focused on drug discovery for rare diseases, with gene editing among its capabilities and KAIMRC scientists training at AstraZeneca’s Gothenburg site. The partnership’s return to the Summit three years later illustrates the kind of continuity the market should look for.
On the clinical side, the University Hospitals Program at the Council of Universities’ Affairs signed with Novo Nordisk to build clinical trial capability. The scope explicitly includes earlier phase trials. Outside Riyadh, Najran University launched the Najran Genomic Biobank Initiative and the University of Hafr Al Batin partnered with BGI Group.
Manufacturing
Vaccine Industrial Company confirmed that its human vaccine manufacturing facility in Sudair Industrial City, a SAR 500 million (about $133 million) investment across 42,000 square meters, is 85% complete. The company plans for the site to localize up to 80% of the Kingdom’s essential vaccine needs. The next milestones are commissioning, licensing and production. The broader industrial strategy also identifies pharmaceuticals and biopharmaceuticals as areas where government support for local capabilities includes local content policies and incentives such as funding, vocational training and infrastructure.
Capital and regulation
The Life Sciences Innovation Forum received applications from more than 100 companies, nominated more than 25 for investment and engaged five investment funds with a combined willingness to invest more than $120 million. That figure reflects investor interest rather than closed capital and conversion is the number to watch. In one concrete example, Sanabil Studio by Redesign Health signed with Telepath by Tahlili on AI and digital pathology, with a potential investment of $3 million.
The activity sits within a broader investment infrastructure. The Ministry of Investment, a strategic partner of RGMBS, identifies healthcare and biotechnology as priority areas and, through Invest Saudi, is presenting opportunities spanning CRO capacity, gene and cell therapy and biopharma manufacturing. Invest Saudi also provides services covering investment registration, setup and expansion.
The regulatory side is becoming more measurable. The Saudi Food and Drug Authority reported an 83% increase in applications for clinical trials involving advanced therapies and biotechnology products in 2025, while its Reliance Pathway reduced study approval times by 74% compared with the standard track. For global biopharma companies, those changes offer a more practical signal of the operating environment than a policy statement alone.
Talent
Princess Nourah bint Abdulrahman University and Cellenkos launched a program to develop Saudi female talent in cell and gene therapy and biomanufacturing. SVAX and Batterjee Medical College agreed accredited biomanufacturing training with up to 350 seats per cycle. Both address a constraint any new biomanufacturing site will face: qualified operators and scientists.
What to watch
RGMBS, now in its fourth edition, produced more than 40 agreements, initiatives and announcements over three days. Their combined declared value exceeded SAR five billion ($1.33 billion).
These announcements give companies assessing the market a set of concrete markers to watch: the vaccine facility progressing toward production, trial starts under the Novo Nordisk program, forum introductions converting to investments and the first cohorts completing the new training programs. Saudi Arabia is moving from setting targets to putting named partners, scopes and sites behind them. The next phase is to build on that momentum and turn it into measurable outcomes.